Evidence map›Paper›PMID 34192057›Full record

ArticleJournal of clinical and translational science2021

Clinical research during the COVID-19 pandemic: The role of virtual visits and digital approaches.

Tammy L Loucks, Clare Tyson, David Dorr, Vesna D Garovic, James Hill, S David McSwain, Sally Radovick, Frank A Sonnenberg, Jennifer A Weis, Kathleen T Brady

Abstract read
In one paragraph

Article in Journal of clinical and translational science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Impact of the COVID-19 pandemic on CTSA Clinical Research Centers over 2 years.Journal of clinical and translational science · 2023
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Tammy L LoucksSouth Carolina Clinical and Translational Research (SCTR) Institute, Medical University of South Carolina, Charleston, SC, USA.
Clare TysonSouth Carolina Clinical and Translational Research (SCTR) Institute, Medical University of South Carolina, Charleston, SC, USA.
David DorrDepartment of Medical Informatics and Clinical Epidemiology, Oregon Health and Science University, Portland, OR, USA.
Vesna D GarovicDepartment of Internal Medicine, Division of Nephrology and Hypertension and Department of Obstetrics and Gynecology, Mayo Clinic College of Medicine, Rochester, MN, USA.
James HillDepartment of Nutrition Sciences, University of Alabama Birmingham, Birmingham, AL, USA.
S David McSwainDepartment of Pediatrics, Medical University of South Carolina, Charleston, SC, USA.
Sally RadovickDepartment of Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
Frank A SonnenbergDepartment of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
Jennifer A WeisCenter for Clinical and Translational Science (CCATS), Mayo Clinic, Rochester, MN, USA.
Kathleen T BradySouth Carolina Clinical and Translational Research (SCTR) Institute, Medical University of South Carolina, Charleston, SC, USA.

Funding

Oregon Clinical and Translational Research Institute - The National COVID Cohort Collaborative (N3C)UL1TR002369 · NCATS · OREGON HEALTH & SCIENCE UNIVERSITY · PI Cynthia D Morris, Christopher G. Slatore · 2017 to 2026
$78.4M
Mayo Clinic Center for Translational Science ActivitiesUL1TR000135 · NCATS · MAYO CLINIC ROCHESTER · PI KHOSLA, SUNDEEP · 2012 to 2015
$41.2M
South Carolina Clinical & Translational Research Institute (SCTR)UL1TR001450 · NCATS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI BRADY, KATHLEEN T., FLUME, PATRICK A · 2015 to 2024
$41.1M
New Jersey Alliance for Clinical Translational Science: NJ ACTSUL1TR003017 · NCATS · RUTGERS BIOMEDICAL/HEALTH SCIENCES-RBHS · PI PANETTIERI, REYNOLD ALEXANDER · 2019 to 2023
$28.9M
Southern Consortium Node of the Clinical Trials Network (Varenicline)UG1DA013727 · NIDA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI KATHLEEN T. BRADY, Kelly S. Barth · 2015 to 2026
$24.8M
CTSA Coordinating Center for Leading Innovation and Collaboration (CLIC)U24TR002260 · NCATS · UNIVERSITY OF ROCHESTER · PI OSSIP, DEBORAH J, ZAND, MARTIN S · 2017 to 2021
$19.0M
UAB Center for Clinical and Translational Science (CCTS) UL1UL1TR000165 · NCATS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KIMBERLY, ROBERT P. · 2012 to 2013
$9.6M
SPROUT-CTSA Collaborative Telehealth Research NetworkU01TR002626 · NCATS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CHUO, JOHN, MCSWAIN, STEVEN D · 2019 to 2023
$3.6M
NCATS NIH HHS U01 TR002626NCATS NIH HHS U24 TR002260NCATS NIH HHS UL1 TR000135NCATS NIH HHS UL1 TR000165NCATS NIH HHS UL1 TR001450NCATS NIH HHS UL1 TR002369NCATS NIH HHS UL1 TR003017NIDA NIH HHS UG1 DA013727
6 · The paper itself

Abstract

Clinical trials are a fundamental tool in evaluating the safety and efficacy of new drugs, medical devices, and health system interventions. Clinical trial visits generally involve eligibility assessment, enrollment, intervention administration, data collection, and follow-up, with many of these steps performed during face-to-face visits between participants and the investigative team. Social distancing, which emerged as one of the mainstay strategies for reducing the spread of SARS-CoV-2, has presented a challenge to the traditional model of clinical trial conduct, causing many research teams to halt all in-person contacts except for life-saving research. Nonetheless, clinical research has continued during the pandemic because study teams adapted quickly, turning to virtual visits and other similar methods to complete critical research activities. The purpose of this special communication is to document this rapid transition to virtual methodologies at Clinical and Translational Science Awards hubs and highlight important considerations for future development. Looking beyond the pandemic, we envision that a hybrid approach, which implements remote activities when feasible but also maintains in-person activities as necessary, will be adopted more widely for clinical trials. There will always be a need for in-person aspects of clinical research, but future study designs will need to incorporate remote capabilities.

Indexed as

clinical trialsCOVID-19 pandemicvirtual systems

Identifiers

PMID34192057
PMCPMC8185429

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.